Overview
The purpose of this study is to find out whether Contrast-Enhanced Mammography/CEM scans performed 2 minutes and 6 minutes after receiving Iohexol contrast dye can be used to identify the amount of residual disease in the breast following neoadjuvant treatment.
Eligibility
Inclusion Criteria:
- Any women >18 years of age at time of informed consent
- Diagnosed with breast cancer and schedule for NAT
Exclusion Criteria:
- History of kidney disease, creatinine level >1.3 or eGFR <45.
- Known allergic reaction to gadolinium or iodinated contrast media.
- Contraindication to contrast-enhanced breast MRI.
- Lesion not included in the field of view of either pre- or post-NAT MRI or CEM
- Presence of pacemakers or automated implantable cardioverter defibrilator
- Pregnant women